VALARTH See Wockhardt in the appOpen in app
WOCKPHARMA · NSE · Pharmaceuticals

Wockhardt Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Small Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
dear low confidence No valuation within 120 days; P/E 79.2 vs peers 36.0 (18th of 22); P/B 6.2 vs peers 5.1 (16th of 25).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Wockhardt's share price today?

Wockhardt last traded at ₹1,963.20 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 1.7% on the day, up 43.8% over a year. Its 52-week range is ₹1,087 to ₹2,422. The live price is in the app.

₹1,963.20 −1.7% today
+43.8% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 30 Apr 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range66% of the way up
Low ₹1,087High ₹2,422

What is Wockhardt's market cap?

Wockhardt's market capitalisation is about ₹32,440 crore: what it would cost to buy every share at today's price. That makes it the 28th largest small cap company we cover.

₹32,440 Cr Small Cap28th largest small cap company
Small Cap means the companies ranked 251 and below by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: WOCKPHARMA
ISIN
INE049B01025
Cap bucket
Small Cap, 28th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2000
Futures and options
Not traded

Is Wockhardt overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 79.2 vs peers 36.0 (18th of 22); P/B 6.2 vs peers 5.1 (16th of 25).

Valuation

Latest price and trailing 12 months
P/E 79.22
vs peers 36.0 · 18th of 22
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 6.18
vs peers 5.1 · 16th of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹32,440 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield Not available
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 2.41
vs peers 2.4 · 9th of 19
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth Not available
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
2 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; P/E vs own history: 60 of 36 months of P/E history

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Wockhardt a quality business?

Quality score 35.1, 20th of 24 in its peer set; WATCH on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 35.1
vs peers 53.7 · 20th of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 9.9%
vs peers 16.2% · 18th of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 9.6%
vs peers 19.1% · 20th of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 11.0%
vs peers 15.8% · 17th of 24
Profit after everything, as a share of revenue. Learn more →
EPS ₹12.28
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Wockhardt made money for shareholders?

Yes: +43.8% over one year and +36.0% a year over five years.

Shareholder returns

1-year return +43.8%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +36.0% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−3.2%
1M
−3.3%
3M
+7.7%
6M
+46.5%
1Y
+43.8%
3Y
+110.5%
5Y
+36.0%

Does Wockhardt pay a dividend?

Wockhardt last paid ₹9.22 a share, ex-dividend 17 Nov 2016; nothing in the past 12 months counts toward a yield.

Dividends

Per share, by ex-dividend date
17 Nov 2016 · Interim₹9.22
13 Nov 2014 · Interim₹18.44
17 Feb 2014 · Interim 2₹4.61
7 Nov 2013 · Interim₹4.61
22 Aug 2013 · Final₹4.61
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Wockhardt growing?

Revenue 3 years 7.9% a year; revenue 5 years 2.7% a year; eps 5 years -25.5% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 7.9% a year
vs peers 14.5% · 19th of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years Not available
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 2.7% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years Not available
Compound annual growth of net profit over five years. Learn more →
EPS 3 years Not available
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years -25.5% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history Not available
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Wockhardt do last quarter?

Wockhardt reported revenue of ₹929 Cr, up 12.0% on a year earlier and a net profit of ₹107 Cr, down 449.1% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹929 Cr
+12.0% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹107 Cr
−449.1% on a year earlier
What was left for shareholders after every cost and tax.

How does Wockhardt compare with its peers?

Compared with 24 Pharmaceuticals; 18th of 22 on P/E; 20th of 24 on quality score.

Compared with 24 Pharmaceuticals

24 companies

Wockhardt against its peers

Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Wockhardt Ltd₹32,440 Cr79.26.29.9%9.6%+43.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Alkem Laboratories Ltd₹63,118 Cr29.34.517.3%18.8%−3.9%
Biocon Ltd₹56,942 Cr102.82.20.9%1.6%—
Abbott India Ltd₹55,250 Cr34.211.534.5%43.8%−13.3%
Gland Pharma Ltd₹50,523 Cr44.72.612.6%17.1%+58.8%
Ipca Laboratories Ltd₹48,595 Cr36.05.115.2%19.5%+44.7%
Glaxosmithkline Pharmaceuticals Ltd₹43,034 Cr41.017.348.3%58.2%−7.6%
Ajanta Pharma Ltd₹42,612 Cr37.58.324.1%30.6%+41.0%
J B Chemicals & Pharmaceuticals Ltd₹38,677 Cr—8.218.2%24.2%+45.1%
Emcure Pharmaceuticals Ltd₹34,783 Cr34.48.221.8%22.8%+33.8%
Peer median—36.05.116.2%19.1%+28.0%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Wockhardt?

Wockhardt is held by promoters 49.1%, foreign institutions 7.2%, domestic institutions 9.2%.

Shareholding pattern

Latest filing, percent of shares
Promoters49.1%
The founders and controlling group.
Foreign institutions7.2%
Overseas funds investing through the FPI route.
Domestic institutions9.2%
Indian insurers, banks, pension and mutual funds together.
Mutual funds6.8%
Indian mutual fund schemes; part of domestic institutions.
Retail and others19.5%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What does Wockhardt do and what is it sensitive to?

Wockhardt Limited is a pharmaceutical company whose products are marketed in about 40+ countries, sold through stockiests, institutions and dealers, with patients as end consumers. Sensitive to: interest rates on variable-rate borrowings.

Business-model card

FY2025 · 37 verified
2Revenue
2Channels
3Regulators
4Reg. dependencies
4Sensitivities
4Costs
5Geographies

Wockhardt Limited is a pharmaceutical company whose products are marketed in about 40+ countries, sold through stockiests, institutions and dealers, with patients as end consumers. It earns mainly from sale of pharmaceutical products, recognised when control transfers to the buyer, plus out-licensing fees and sales of intellectual property.

Revenue by segment

year ended March 31, 2025 (consolidated; single reportable pharmaceutical segment)
External revenue in the above reportable business segment100.0%

Revenue engine

2 verified
Pharmaceutical products (sole reportable segment)
Company states it is exclusively in pharmaceuticals; revenue from goods is recognised when control transfers to the buyer, net of rebates, discounts and returns. Interpretation: product sales are net of rebate and return accruals that depend on buying-group arrangements.
Out-licensing fees and sale of intellectual property
Recognised per the terms of each agreement when control transfers and performance obligations are met, so timing depends on contract terms.

Customers & channels

2 verified
Stockiests and institutions as direct customers; patients as end consumers
Direct customers are stockiests and institutions, and patients consume the product. Interpretation: pricing and trade terms are set with the direct channel, not the patient.
No single major customer
Company states no customer exceeds 10% of total revenue, so concentration risk from one buyer is not stated as material.

Regulators

3 verified
National Pharmaceutical Pricing Authority (NPPA)
Governs drug pricing; the excerpt records a demand from NPPA disclosed as a contingent liability.
Income tax authorities
Tax demands raised by income tax authorities are disputed by the Company and carried as contingent liabilities.
Government pricing regulation (unnamed authority)
Government regulation sets price caps on specified medical products, which affect realised prices on those products.

Regulatory dependencies

4 verified
Price caps on specified medical products
A cap lowers realised price and therefore revenue and margin on capped products. Interpretation: a tighter cap would reduce revenue and profit on those products; the filing says caps could shrink profitability.
cGMP and quality compliance
Non-compliance can halt output and bring penalties, which reduces production volume and adds cost. Interpretation: stricter cGMP standards raise compliance spend.
Tax and other statutory demands under dispute
Disputed demands are carried as contingent liabilities; an adverse outcome would be a cash cost outside normal operations.
1 more statement
Export benefit schemes
Export incentives are accrued as revenue only when conditions are expected to be met, so a change in schemes changes reported revenue.

Sensitivities

4 verified
Interest rates on variable-rate borrowings
Company discloses a 100 basis point sensitivity on variable-rate instruments, with the profit-before-tax effect shown for increase and decrease. Interpretation: a rate rise lowers profit before tax; a fall raises it.
Foreign currency exchange rates
Company is exposed through operations in other countries, with the functional currency being the Indian Rupee; the exposure is partly offset by natural hedging.
Trade tariffs and protectionism
Interpretation: new tariffs would raise trade friction for export-heavy sales and could disrupt supply chains. The excerpt describes the risk at global level.
1 more statement
Geopolitical supply chain disruption
Company names volatile geopolitical developments as a possible cause of supply chain disruption, which would affect input availability and cost.

Cost inputs

4 verified
Salaries and wages
Largest employee cost line in the standalone employee benefits note, rising from 222 crore to 236 crore.
Stores and spare parts
Operating expense line for consumables used in operations, shown as 33 crore in FY2025 and 18 crore in FY2024.
Freight and forwarding
Logistics cost line in other expenses, shown as 20 crore in FY2025 and 24 crore in FY2024.
1 more statement
Procured materials and manufacturing overheads
Inventory cost is a moving weighted average of procured materials plus a share of labour and manufacturing overheads.

Geographies

5 verified
European Union (12.0%)
Revenue segment of the group; contributed 12% of revenue in FY2025, down from 13% in FY2024.
United Kingdom (39.0%)
Operations contributed 39% of revenue, up from 37% in FY2024.
India and Rest of the world (46.0%)
Combined share of revenue; the company states India and rest of world together contributed 46%, up from 44%.
2 more statements
Exports as share of turnover
Company states exports are 51% of total turnover.
Geographic revenue basis
Revenue by geography is assigned by ultimate utilisation of the product, not by invoicing location.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (10 Aug 2026).

Change log

8 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Results filedQ4 FY2026 results filed.
  3. Results filedQ3 FY2026 results filed.
  4. Results filedQ2 FY2026 results filed.
  5. Results filedQ1 FY2026 results filed.
  6. Results filedQ4 FY2025 results filed.
  7. Corporate actionAnnual General Meeting.
  8. Corporate actionAnnual General Meeting.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; P/E vs own history: 60 of 36 months of P/E history.
  • FlagsWATCH on 30 of 30 flags judged; 1 red.
  • Data gapsDividend yield, PEG on our 3-year EPS growth, Business quality, Profit 3 years, Profit 5 years, EPS 3 years and 1 more: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓269 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2025 · 37 verified

Questions people ask

What is Wockhardt's share price today?

Wockhardt last traded at ₹1,963.20 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 1.7% on the day, up 43.8% over a year. Its 52-week range is ₹1,087 to ₹2,422. The live price is in the app.

What is Wockhardt's market cap?

Wockhardt's market capitalisation is about ₹32,440 crore: what it would cost to buy every share at today's price. That makes it the 28th largest small cap company we cover.

Is Wockhardt Ltd a large cap, mid cap or small cap?

Wockhardt Ltd (WOCKPHARMA) is a small cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Wockhardt Ltd's P/E ratio?

79.22, vs peers 36.0 · 18th of 22. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Wockhardt Ltd overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 79.2 vs peers 36.0 (18th of 22); P/B 6.2 vs peers 5.1 (16th of 25).

How does Wockhardt Ltd make money?

Wockhardt Limited is a pharmaceutical company whose products are marketed in about 40+ countries, sold through stockiests, institutions and dealers, with patients as end consumers. It earns mainly from sale of pharmaceutical products, recognised when control transfers to the buyer, plus out-licensing fees and sales of intellectual property.

Who are Wockhardt Ltd's peers?

Compared with 24 Pharmaceuticals: Glenmark Pharmaceuticals Ltd, Alkem Laboratories Ltd, Biocon Ltd, Abbott India Ltd, Gland Pharma Ltd and 19 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Wockhardt do last quarter?

Wockhardt reported revenue of ₹929 Cr, up 12.0% on a year earlier and a net profit of ₹107 Cr, down 449.1% in the Jun 2026 quarter.

Who owns Wockhardt?

Wockhardt is held by promoters 49.1%, foreign institutions 7.2%, domestic institutions 9.2%.

Does Wockhardt pay a dividend?

Wockhardt last paid ₹9.22 a share, ex-dividend 17 Nov 2016; nothing in the past 12 months counts toward a yield.

Everything on Wockhardt, and 6,621 other companies, with 212 filters and the full peer tables

See Wockhardt in the app →See pricing